High density lipoprotein-reactive peptides

Details High density lipoprotein-reactive peptides High density lipoprotein-reactive peptides

2007-07-10

2007-07-10

Kemmerer, Elizabeth (Department: 1646)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

25 or more amino acid residues in defined sequence

C514S012200

Reexamination Certificate

active

10476872

ABSTRACT:
A high-density lipoprotein-reactive peptide or a foam cell-reactive peptide as set forth in the following (a) or (b): (a) a peptide comprising the amino acid sequence represented by SEQ ID NO: 1; and (b) a peptide comprising an amino acid sequence derived from the amino acid sequence as specified in the above (a) by substitution, deletion, addition, or insertion of one or more amino acid residues and being capable of specifically binding to high-density lipoprotein cholesterol or withdrawing cholesterol from foam cells. Thus, peptides having novel amino acid sequences and being capable of specifically binding to HDL cholesterol or withdrawing cholesterol from foam cells are provided. These peptides are useful as drugs for various diseases caused by arteriosclerosis, lipid metabolic errors, and peripheral cholesterosis.

REFERENCES:
patent: 6635623 (2003-10-01), Hoogeveen et al.
patent: 63-243878 (1988-10-01), None
patent: 6-138122 (1994-05-01), None
patent: 87/02062 (1987-04-01), None
patent: 97/43311 (1997-11-01), None
patent: 98/56938 (1998-12-01), None
NCBI Protein Database Accession No. P04114 (Nov. 1, 1986).
Ylitalo et al. 1999. Life Sciences. 64(21): 1955-1965.
Moghadasian, 2002. Life Sciences. 70: 855-865.
Maxfield et al, 2005, Nature. 438(7068): 612-621.
Knott et al, 1986. Nucleic Acids Research, 14(18): 7501-7503.
Wells (Sep. 18, 1990) Biochemistry 29(37): 8509-8517.
Ngo et al. (Mar. 2, 1995) “The Protein Folding Problem and Tertiary Structure Prediction, Chapter 14: Computational Complexity Protein Structure Prediction, and the Levinthal Paradox” pp. 492-495.
Bork (2000) Genome Research 10:398.
Skolnick and Fetrow (2000) Trends in Biotech. 18(1): 34.
Doerks et al. (Jun. 1998) Trends in Genetics 14(6): 248.
Smith and Zhang (Nov. 1997) Nature Biotechnology 15:1222.
Brenner (Apr. 1999) Trends in Genetics 15(4): 132.
Bork and Bairoch (Oct. 1996) Trends in Genetics 12(10): 425.
Frei et al, 1992 (Journal of Cell Biology, 118(1): 177-194).
Dhople et al (2005, Peptides, 26: 217-225).
Guerrini et al (2000, Peptides, 21: 923-933).
Medical Practice, vol. 18, No. 3, pp. 473-480, With Partial English Translation 2001, Authors: Sakai and Yamasita.
Domyakukoka, vol. 20, No. 2-3, pp. 79-88, With English Summary, 1992, Authors: Nakajima et al.
Katsuyuki Nakajima, et al., “Cholesterol in remnant-like lipoproteins in human serum using monoclonal anti apo B-100 and anti apo A-I immunoaffinity mixed gels”, Clinica Chimica Acta 223, pp. 53-71 1993.
David W. Garber, et al., “A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis”, Journal of Lipid Research, vol. 42, No. 4, XP-002314523, Apr. 2001, pp. 545-552.
Odette S. Reyes, et al., “Immunization With a Novel Human Apo B100 Related Peptide Reduces Atherosclerosis and Inflammation in Apo E Null Mice”, Journal of the American College of Cardiology, vol. 39, No. 5, XP-009042981, Mar. 6, 2002, p. 240A.

Affiliated with

Also associated with

Rating

High density lipoprotein-reactive peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with High density lipoprotein-reactive peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and High density lipoprotein-reactive peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3754706